Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.68 |
| ▸ | HTR3B | O95264 | 3/20 | 0.68 |
| ▸ | HTR3A | P46098 | 3/20 | 0.68 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.68 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4553876 | 0.84 | HTR3E (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1515249 | 0.84 | HTR3E (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL31415224 | 0.84 | HTR3E (0.72) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6467644 | 0.82 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Ammonia Solution, Strong SCHEMBL28500104 | 0.82 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Ammonia Solution, Strong SCHEMBL28466868 | 0.82 | HTR3E (0.70) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL2127461 | 0.81 | HTR3A (1.00) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Ammonia Solution, Strong SCHEMBL28472249 | 0.79 | HTR3A (0.96) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL1515189 | 0.79 | HTR3E (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL75430 | 0.79 | HTR3E (0.66) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2465504-A1 | Novel 2,3-diamino-quinazolinone derivatives and their medical use | NeuroSearch A/S (DK) | 2012-06-20 | — | — | EP | disclosed |
| US-8178544-B2 | 2, 3-diamino-quinazolinone derivatives and their medical use | NEUROSEARCH A/S (DK) | 2012-05-15 | — | — | US | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEURO SEARCH A/S (DK) | 2010-06-24 | — | — | US | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2152272-A2 | NOVEL 2,3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NeuroSearch A/S (DK) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008142140-A2 | NOVEL 2,3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | NEUROSEARCH A/S (DK) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160315-A1 | NOVEL 2, 3-DIAMINO-QUINAZOLINONE DERIVATIVES AND THEIR MEDICAL USE | KCNJ2, KCNN3, KCNK17 | HTR3E 462/4885HTR3B 357/4885HTR3A 557/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | HTR3E 679/4885HTR3B 528/4885HTR3A 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.